Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease

Mostrar todas las versiones(2)

Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Pérez Lloret, Santiago, Cardinali, Daniel Pedro
Formato: Artículo
Lenguaje:Inglés
Publicado: Frontiers Media 2021
Materias:
MELATONINA
ENFERMEDAD DE PARKINSON
ENVEJECIMIENTO
NEURODEGENERACION
ENFERMEDADES NEURODEGENERATIVAS
TRATAMIENTO MEDICO
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/11620
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139-123456789-11620
record_format dspace
spelling I33-R139-123456789-116202023-11-22T21:53:45Z Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease Pérez Lloret, Santiago Cardinali, Daniel Pedro MELATONINA ENFERMEDAD DE PARKINSON ENVEJECIMIENTO NEURODEGENERACION ENFERMEDADES NEURODEGENERATIVAS TRATAMIENTO MEDICO Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect. 2021-06-14T16:58:00Z 2021-06-14T16:58:00Z 2021 Artículo Pérez Lloret, S., Cardinali, D. P. Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease [en línea]. Frontiers in pharmacology. 2021, 12 (650597). doi:10.3389/fphar.2021.650597. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11620 1663-9812 https://repositorio.uca.edu.ar/handle/123456789/11620 10.3389/fphar.2021.650597 33935759 eng Acceso abierto http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Frontiers Media Frontiers in pharmacology Vol.12, Art.650597, 2021
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic MELATONINA
ENFERMEDAD DE PARKINSON
ENVEJECIMIENTO
NEURODEGENERACION
ENFERMEDADES NEURODEGENERATIVAS
TRATAMIENTO MEDICO
spellingShingle MELATONINA
ENFERMEDAD DE PARKINSON
ENVEJECIMIENTO
NEURODEGENERACION
ENFERMEDADES NEURODEGENERATIVAS
TRATAMIENTO MEDICO
Pérez Lloret, Santiago
Cardinali, Daniel Pedro
Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
topic_facet MELATONINA
ENFERMEDAD DE PARKINSON
ENVEJECIMIENTO
NEURODEGENERACION
ENFERMEDADES NEURODEGENERATIVAS
TRATAMIENTO MEDICO
description Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect.
format Artículo
author Pérez Lloret, Santiago
Cardinali, Daniel Pedro
author_facet Pérez Lloret, Santiago
Cardinali, Daniel Pedro
author_sort Pérez Lloret, Santiago
title Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title_short Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title_full Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title_fullStr Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title_full_unstemmed Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title_sort melatonin as a chronobiotic and cytoprotective agent in parkinson’s disease
publisher Frontiers Media
publishDate 2021
url https://repositorio.uca.edu.ar/handle/123456789/11620
work_keys_str_mv AT perezlloretsantiago melatoninasachronobioticandcytoprotectiveagentinparkinsonsdisease
AT cardinalidanielpedro melatoninasachronobioticandcytoprotectiveagentinparkinsonsdisease
_version_ 1807949103239266304

Ejemplares similares